Kaftrio

Tezacaftor/Elexacaftor/Ivacaftor, the active ingredient in Kaftrio, is a CFTR modulator presented as a tablet for oral use. It treats cystic fibrosis in patients aged 12 years and older who have at least one F508del mutation.

GNH USA supplies Kaftrio as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Kaftrio is a CFTR modulator indicated for cystic fibrosis, a genetic disease affecting the respiratory and digestive systems. - Cystic fibrosis with one F508del allele: Improves lung function and reduces pulmonary exacerbations. - Cystic fibrosis with two F508del alleles: Further enhances sweat‑chloride levels and respiratory outcomes. - Cystic fibrosis patients aged 12 years and older: Decreases the frequency of severe respiratory infections and improves overall health status.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhea: occasional loose stools. - Abdominal pain: mild discomfort. - Rash: skin redness or itching. - Nasopharyngitis: cold‑like symptoms. - Elevated liver enzymes: mild increase in ALT/AST.

Serious or Rare Side Effects: - Significant liver injury: jaundice or marked enzyme rise. - Cataracts or retinal pigment changes: visual disturbances. - Severe allergic reactions: swelling, hives, or anaphylaxis. - Pulmonary hemorrhage: coughing up blood. - Acute pancreatitis: severe abdominal pain with nausea. - Myopathy: muscle weakness or pain.

Kaftrio requires careful monitoring and patient education before and during therapy. - Liver function monitoring: check ALT/AST regularly. - Drug interaction awareness: review concomitant medications. - Pregnancy and breastfeeding: discuss risks with a healthcare professional. - Age considerations: not recommended for children under 12 years. - Adherence importance: take tablets exactly as prescribed. - Store at ambient temperature: keep in the original pack, protect from moisture.

Kaftrio may interact with several drug classes, requiring dose adjustments or avoidance. Major Interactions (Avoid): - Strong CYP3A inducers (e.g., rifampin): may reduce efficacy. - Strong CYP3A inhibitors (e.g., ketoconazole): may increase toxicity. - Certain macrolide antibiotics (e.g., clarithromycin): risk of elevated drug levels. Moderate Interactions (Monitor Closely): - Warfarin: monitor INR for anticoagulation changes. - Oral contraceptives: assess hormonal efficacy. - Statins (e.g., simvastatin): watch for increased muscle toxicity. - Antifungal azoles (e.g., itraconazole): adjust dosing as needed. - Proton pump inhibitors: may affect absorption of ivacaftor.